Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [6190]

ESMO 2019: Immune therapy eliminates tumour cells in early triple negative breast cancer

ESMO 2019: Immune therapy eliminates tumour cells in early triple negative breast cancer

ESMO 2019: More ovarian cancer patients benefit from maintenance combined targeted therapy

ESMO 2019: More ovarian cancer patients benefit from maintenance combined targeted therapy

ESMO 2019: Front-line osimertinib improves overall survival in EGFR-mutation positive NSCLC

ESMO 2019: Front-line osimertinib improves overall survival in EGFR-mutation positive NSCLC

ESMO 2019: Two immunotherapy drug combination offers chemotherapy-free option for advanced NSCLC

ESMO 2019: Two immunotherapy drug combination offers chemotherapy-free option for advanced NSCLC

ESMO 2019: Clinical benefit with first-line immunotherapy in advanced hepatocellular carcinoma

ESMO 2019: Clinical benefit with first-line immunotherapy in advanced hepatocellular carcinoma

ESMO 2019: New studies question whether novel anti-cancer drugs are worth their extra cost

ESMO 2019: New studies question whether novel anti-cancer drugs are worth their extra cost

Oncologists respond swiftly to FDA safety alerts

Oncologists respond swiftly to FDA safety alerts

Researchers apply fat cells to deliver drug to suppress tumour growth

Researchers apply fat cells to deliver drug to suppress tumour growth

Resistance to immune checkpoint blocker drug linked to metabolic imbalance

Resistance to immune checkpoint blocker drug linked to metabolic imbalance

Investigational drug with immunotherapy may provide new therapeutic opportunity for patients previously treated for kidney and lung cancer

Investigational drug with immunotherapy may provide new therapeutic opportunity for patients previously treated...

More from ecancer